Protea Licenses Mass Spec Technology from GWU | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protea Biosciences today announced a worldwide licensing agreement with George Washington University for mass spectrometry-based technology.

The technology, called Laser Ablation Electrospray Ionization, or LAESI, can directly identify proteins, peptides, lipids, and metabolites in biological samples, including tissue, blood, urine, and single cells, Protea said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.